Listen to this Post
Boston Scientific has announced plans to acquire Israeli-based medical device company, SoniVie, in a deal valued at up to $540 million. This move highlights the growing interest in non-traditional hypertension treatments, especially as research into renal denervation (RDN) therapies gains momentum. The acquisition will see Boston Scientific expanding its portfolio with a promising new technology, the TIVUS (Therapeutic Intravascular Ultrasound) system, which could offer an alternative to conventional blood pressure medications. This acquisition places Boston Scientific at the forefront of an exciting shift in how hypertension could be treated in the future.
Key Points:
Boston Scientific is acquiring SoniVie for $540 million, with a payment of $360 million in cash and up to $180 million in milestone payments. The focus is on SoniVie’s innovative TIVUS system, which uses ultrasound energy to treat hypertension by disrupting nerve signals in the renal arteries. Hypertension, a leading cause of heart disease and stroke, is resistant to medication in many patients, making this new approach potentially transformative.
The TIVUS system has shown promise in clinical trials and has received FDA breakthrough device designation for renal artery denervation and pulmonary arterial hypertension. The acquisition is expected to close in 2025, pending regulatory approvals. Boston Scientific aims to enhance its cardiovascular treatment offerings, with an emphasis on minimally invasive therapies for hypertension. The move also highlights the growing role of ultrasound energy in medical treatments, offering deeper tissue penetration and faster procedures compared to traditional radiofrequency methods.
What Undercode Says:
Boston
Renal denervation, particularly ultrasound-based treatments like TIVUS, is seen as a game-changer in the field of hypertension management. Studies have shown that this approach can potentially reduce nerve activity in the kidneys, a key player in blood pressure regulation. The promise of long-term solutions for patients who struggle with medications is what makes this acquisition particularly noteworthy. The move could pave the way for Boston Scientific to expand its cardiovascular offerings, complementing its existing interventional cardiology portfolio.
Additionally, the TIVUS system’s FDA breakthrough device designation underscores the potential of ultrasound energy as a key player in cardiovascular treatments. As the healthcare industry continues to evolve, ultrasound technology is emerging as a safe, effective, and efficient method for treating a variety of conditions. This acquisition not only positions Boston Scientific to lead the way in hypertension treatments but also opens doors for other cardiovascular applications that could improve patient outcomes globally.
The financial terms of the deal—$360 million in cash, with up to $180 million tied to regulatory milestones—reflect the confidence Boston Scientific has in the potential of this technology. The company’s strategic interest in renal denervation and its plans for internal cost efficiencies also highlight the increasing demand for innovative medical devices and therapies. This deal could signal a major shift in the treatment of hypertension, marking a move away from traditional medications and toward more personalized, effective solutions.
Fact Checker Results:
- The deal is valued at up to $540 million, with $360 million paid in cash and additional payments based on regulatory achievements.
- The TIVUS system, which uses ultrasound energy to treat hypertension, has shown positive results in pilot studies and has received FDA breakthrough designation.
3. Boston
References:
Reported By: Calcalistechcom_7013a39de1d4e65845eece11
Extra Source Hub:
https://www.pinterest.com
Wikipedia: https://www.wikipedia.org
Undercode AI
Image Source:
OpenAI: https://craiyon.com
Undercode AI DI v2
